Protalix BioTherapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $215.9M
- Price
- $2.68
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.11%
- Volume
- 610.5K
About
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Quick stats
Shares outstanding80.6M
Computed float75.0M
Float / shares93.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001006281
Websitehttps://www.protalix.com
AI Summary
AI-generated1/12
minorneutralother
REG-Pluxee releases a global study uncovering three paradoxes shaping employee engagement in the era of inflation and AI
Pluxee published its second global employee engagement study, surveying 11,000 employees across 14 countries via Ipsos.
The study identifies three paradoxes: employees are less work-centric yet more connected to their employers, loyalty is increasingly conditional despite financial stress, and workers view AI as more opportunity than threat.
Key findings include 87% of employees saying they love or like their company (up 4 points), inflation cited as the top concern by 70%, and 65% holding a positive attitude toward AI at work.
The release is brand-building thought leadership for Pluxee's employee benefits and engagement business, with no financial or operational disclosure.